Testing the Addition of the Anti-cancer Drug, Cabozantinib, to the Usual Immunotherapy Treatment, Avelumab, in Patients With Metastatic Urothelial Cancer, MAIN-CAV Study
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
City of Hope Medical Center
Georgetown University
University of Colorado, Denver
Hoffmann-La Roche
Emory University
Dana-Farber Cancer Institute
Indiana University
M.D. Anderson Cancer Center
University of Arizona
Emory University
City of Hope Medical Center
Exelixis
Exelixis
Washington University School of Medicine
M.D. Anderson Cancer Center
Memorial Sloan Kettering Cancer Center
Washington University School of Medicine
National Cancer Institute (NCI)
Exelixis
Memorial Sloan Kettering Cancer Center
Exelixis
Grupo Espanol de Tumores Neuroendocrinos
Exelixis
Exelixis
University of California, Irvine
National Cancer Institute (NCI)
Bristol-Myers Squibb
Eli Lilly and Company